BioSpace News Archive

In recognition of John Muir Health’s long-standing commitment to innovation and advancement of patient care, the health system’s Concord Medical Center has been designated as a Foregut Mentor Site for da Vinci® Xi Surgical System robotic procedures.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 14 at the Hilton San Francisco Union Square.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata.

A team led by Professor Patrick Labonté at the Institut National de la Recherche Scientifique has identified the role of a key process in the replication cycle of the hepatitis D virus, an infection that is still very difficult to cure and affects 15 to 20 million people worldwide.

Last year, during the holiday season, police officers were called to a South Carolina residence and discovered a neglected six-year-old Great Dane tied to a pole in his owners’ backyard.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3 PM (PST) in San Francisco.

BrainStorm Cell Therapeutics, Inc. announced that the clinical trial independent Data Safety Monitoring Board has completed the first, pre-specified interim analysis, of safety outcomes for 9 participants enrolled in the Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, announced today the appointment of Corazon “Corsee” Dating Sanders, Ph.D. to its board of directors, effective immediately.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has licensed IONIS-MAPTRx, an antisense therapy designed to selectively reduce production of microtubule-associated protein tau (MAPT), or tau, in the central nervous system.